InvestorsHub Logo
Followers 73
Posts 6235
Boards Moderated 0
Alias Born 05/01/2011

Re: wmartin100 post# 225030

Tuesday, 11/12/2019 5:27:03 PM

Tuesday, November 12, 2019 5:27:03 PM

Post# of 429382
Yes, good framing

The FDA is conceding the secondary group from the trial, and then asking for input on how far to go beyond that.

The docs do NOT have the tone of saying, "Just secondary". They have the tone of saying, "Maybe we should just stick to Cohort 2 -- the primary prevention group from the trial."

In other words, the best case scenario from the dumb GS guy's report.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News